EcoDrugPlus

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSELUG00000021415
Gene Symbol: F2RL3
4 Cross references
191 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSELUG00000000612
Gene Symbol: FAU
3 Cross references
240 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSELUG00000018218
Gene Symbol: FYN
3 Cross references
195 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSELUG00000006077
Gene Symbol: GPR119
4 Cross references
176 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSELUG00000009250
Gene Symbol: HCK
3 Cross references
203 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSELUG00000006111
Gene Symbol: ITK
1 Cross references
208 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSELUG00000022457
Gene Symbol: JAK1
1 Cross references
214 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSELUG00000004988
Gene Symbol: JAK1
1 Cross references
167 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSELUG00000007410
Gene Symbol: JAK2
3 Cross references
197 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSELUG00000003058
Gene Symbol: KRAS
3 Cross references
208 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSELUG00000012494
Gene Symbol: LYN
3 Cross references
196 Possible Orthologues:

Lanc Like 2

Ensembl ID : ENSELUG00000023440
Gene Symbol: LANCL2
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).